- Home
- AZTR vs ZVSA Comparison
AZTR vs ZVSA Comparison
Compare AZTR & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTR
- ZVSA
- Stock Information
- Founded
- AZTR 2014
- ZVSA 2014
- Country
- AZTR United States
- ZVSA United States
- Employees
- AZTR N/A
- ZVSA N/A
- Industry
- AZTR Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- AZTR Health Care
- ZVSA Health Care
- Exchange
- AZTR Nasdaq
- ZVSA Nasdaq
- Market Cap
- AZTR 3.2M
- ZVSA 3.5M
- IPO Year
- AZTR 2023
- ZVSA N/A
- Fundamental
- Price
- AZTR $0.29
- ZVSA $1.29
- Analyst Decision
- AZTR
- ZVSA Strong Buy
- Analyst Count
- AZTR 0
- ZVSA 1
- Target Price
- AZTR N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- AZTR 4.7M
- ZVSA 2.1M
- Earning Date
- AZTR 03-14-2025
- ZVSA 03-24-2025
- Dividend Yield
- AZTR N/A
- ZVSA N/A
- EPS Growth
- AZTR N/A
- ZVSA N/A
- EPS
- AZTR N/A
- ZVSA N/A
- Revenue
- AZTR $97,500.00
- ZVSA N/A
- Revenue This Year
- AZTR N/A
- ZVSA N/A
- Revenue Next Year
- AZTR N/A
- ZVSA N/A
- P/E Ratio
- AZTR N/A
- ZVSA N/A
- Revenue Growth
- AZTR N/A
- ZVSA N/A
- 52 Week Low
- AZTR $0.23
- ZVSA $0.98
- 52 Week High
- AZTR $38.10
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- AZTR 44.02
- ZVSA 47.16
- Support Level
- AZTR $0.24
- ZVSA $1.24
- Resistance Level
- AZTR $0.59
- ZVSA $1.54
- Average True Range (ATR)
- AZTR 0.05
- ZVSA 0.10
- MACD
- AZTR 0.01
- ZVSA -0.02
- Stochastic Oscillator
- AZTR 10.56
- ZVSA 16.67
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.